The in vitro resistance of canine staphylococci to trimethoprim and sulphamethoxazole alone and in combination.
The in vitro resistance of 40 strains of Staphylococcus aureus isolated from dogs to trimethoprim, sulphamethoxazole and co-trimoxazole (SXT) was assessed using the disc diffusion technique on Diagnostic Sensitivity Test Agar (DSTA), DSTA with 5% lysed horse blood (DSTA + B), IsoSensitest Agar (ISTA) and Wellcotest Sensitivity Test Agar (WSTA). When sensitivity was based on a zone width of greater than or equal to 4 mm all 40 strains were sensitive to SXT on DSTA + B and ISTA, 39 were sensitive on WSTA while only 31 (77.5%) were sensitive on DSTA. A comparison of the results obtained for each strain for trimethoprim and sulphamethoxazole with those obtained with the Oxford strain of S. aureus and using a scheme for interpretation recommended by Garrod & O'Grady (1971) indicated that the proportion of strains classed as sensitive for therapeutic purposes was 5%, 55%, 47.5% and 15% respectively on DSTA, DSTA + B, ISTA and WSTA.
D000818:Animals; D004283:Dog Diseases / Q000382:microbiology*; D004285:Dogs; D004338:Drug Combinations / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D008826:Microbial Sensitivity Tests; D013203:Staphylococcal Infections / Q000382:microbiology / Q000662:veterinary; D013210:Staphylococcus / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000494:pharmacology*; D014295:Trimethoprim / Q000494:pharmacology*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole